FAM3A and metabolic dysfunction-associated steatotic liver disease: Given the crucial roles played by repressed ATP synthesis and release in the pathogenesis of diabetes and NAFLD, our findings reveal that targeting FAM3A represents an attractive strategy for combating metabolic disorders.